These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 30660748)

  • 1. Cardiovascular therapies utilizing targeted delivery of nanomedicines and aptamers.
    Tan KX; Pan S; Jeevanandam J; Danquah MK
    Int J Pharm; 2019 Mar; 558():413-425. PubMed ID: 30660748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy.
    Fu Z; Xiang J
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.
    Li X; Zhao Q; Qiu L
    J Control Release; 2013 Oct; 171(2):152-62. PubMed ID: 23777885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aptamer-guided nanomedicines for anticancer drug delivery.
    Alshaer W; Hillaireau H; Fattal E
    Adv Drug Deliv Rev; 2018 Sep; 134():122-137. PubMed ID: 30267743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aptamers and their applications in nanomedicine.
    Sun H; Zu Y
    Small; 2015 May; 11(20):2352-64. PubMed ID: 25677591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of nanomedicines for prostate cancer: An update.
    Lakshmanan VK
    Investig Clin Urol; 2016 Jan; 57(1):21-9. PubMed ID: 26966723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted cancer drug delivery with aptamer-functionalized polymeric nanoparticles.
    Zununi Vahed S; Fathi N; Samiei M; Maleki Dizaj S; Sharifi S
    J Drug Target; 2019 Mar; 27(3):292-299. PubMed ID: 29929413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aptamer-Functionalized Nanoparticles as "Smart Bombs": The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment.
    Benedetto G; Vestal CG; Richardson C
    Target Oncol; 2015 Dec; 10(4):467-85. PubMed ID: 25989948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle-Mediated Drug Delivery for the Treatment of Cardiovascular Diseases.
    Pala R; Anju VT; Dyavaiah M; Busi S; Nauli SM
    Int J Nanomedicine; 2020; 15():3741-3769. PubMed ID: 32547026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
    van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biophysical characterization of layer-by-layer synthesis of aptamer-drug microparticles for enhanced cell targeting.
    Tan KX; Danquah MK; Sidhu A; Lau SY; Ongkudon CM
    Biotechnol Prog; 2018 Jan; 34(1):249-261. PubMed ID: 28699244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo Production of RNA Aptamers and Nanoparticles: Problems and Prospects.
    Shanaa OA; Rumyantsev A; Sambuk E; Padkina M
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33800717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aptamer-Based Targeted Drug Delivery Systems: Current Potential and Challenges.
    He F; Wen N; Xiao D; Yan J; Xiong H; Cai S; Liu Z; Liu Y
    Curr Med Chem; 2020; 27(13):2189-2219. PubMed ID: 30295183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticle Based Treatment for Cardiovascular Diseases.
    Gupta P; Garcia E; Sarkar A; Kapoor S; Rafiq K; Chand HS; Jayant RD
    Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):33-44. PubMed ID: 29737265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted drug delivery vehicles mediated by nanocarriers and aptamers for posterior eye disease therapeutics: barriers, recent advances and potential opportunities.
    Zhang T; Jin X; Zhang N; Jiao X; Ma Y; Liu R; Liu B; Li Z
    Nanotechnology; 2022 Jan; 33(16):. PubMed ID: 34965522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MUC1 aptamer-targeted DNA micelles for dual tumor therapy using doxorubicin and KLA peptide.
    Charbgoo F; Alibolandi M; Taghdisi SM; Abnous K; Soltani F; Ramezani M
    Nanomedicine; 2018 Apr; 14(3):685-697. PubMed ID: 29317345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
    Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
    Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances on nanoparticle-based therapies for cardiovascular diseases.
    Soumya RS; Raghu KG
    J Cardiol; 2023 Jan; 81(1):10-18. PubMed ID: 35210166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted delivery of nanomedicines for promoting vascular regeneration in ischemic diseases.
    Zhuang J; Zhang X; Liu Q; Zhu M; Huang X
    Theranostics; 2022; 12(14):6223-6241. PubMed ID: 36168632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.